Ara
Toplam kayıt 6, listelenen: 1-6
Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: Chemotherapy, targeted therapy, hormonal treatment, and future directions
(Asian Pacific Organization for Cancer Prevention, 2015)
Pancreatic neuroendocrine tumors (pNETs) are rare and heterogenous tumors and surgery to remove the primary tumor is the mainstay of treatment for resectable disease. However, curative surgery is often not feasible, because ...
Efficacy and safety profile of COVID-19 vaccine in cancer patients: A prospective, multicenter cohort study
(Future Medicine Ltd, 2022)
Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against ...
Treatment options in patients with metastatic gastric cancer: Current status and future perspectives
(Baishideng Publishing Group, 2014)
Despite advances in the treatment of gastric cancer, it remains the world's second highest cause of cancer death. As gastric cancer is often diagnosed at an advanced stage, systemic chemotherapy is the mainstay of treatment ...
Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of anatolian Society of medical oncology (ASMO)
(Imprimatur Publications, 2016)
Purpose: Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Since these are rarely encountered tumors, there are limited numbers of studies investigating systemic treatment ...
Important factors affecting adjuvant treatment decision in stage IA breast cancer patients in Turkey
(S. Karger AG, 2014)
Introduction: In Turkey, the gene expression profile test is not standard, so adjuvant treatment is planned according to clinicopathological factors. Therefore, we retrospectively analyzed important parameters that affect ...
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
(Imprimatur Publication, 2020)
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of ...